INTRODUCTION
In metastatic CRC, these molecularly targeted agents are being developed for their effects on pathways characteristic of tumors, including those that regulate cell growth, the cell cycle, apoptosis, angiogenesis, and invasion [4, 5] . Angiogenesis -the formation of new capillaries from the preexisting one-is an essential requirement of solid tumor growth and metastasis. Accordingly, inhibition of angiogenesis has been explored as an antitumor treatment strategy, reflecting the expectation that poorly vascularized tumors would have limited growth potential and restricted metastatic capacity. VEGF, a specific mitogen for endothelial cell proliferation is probably the key mediator of tumor angiogenesis [6, 7] .
The extracellular matrix (ECM) acts as both a physical scaffold for cells and a repository for growth factors.
Structural changes in ECM proteins accomplished by a complex process controlling the expression and activities of matrix metalloproteinases (MMPs), are a prerequisite for cell migration during tissue remodeling. Overexpression of MMPs leads to degradation of the ECM, an essential step for tumor invasion and metastasis. Particular groups of MMPs, notably gelatinases A and B, also known as 72 and 92 kDa type IV collagenases or MMP-2 and MMP-9, respectively, are of particular interest with respect to their roles in the development and progression of CRC [8] [9] [10] .
Cell death can be divided into two categories: apoptosis and necrosis. Apoptosis, or programmed cell death, represents a cell-intrinsic "suicide" mechanism that is regulated by a variety of cellular signaling pathways. In many cases, tumors can be difficult to eliminate because cancer treatments often act by damaging cells with radiation or chemicals, and cause mutations in the apoptotic pathway.
Understanding how apoptosis is regulated in cancer is therefore a major issue in the development of treatments for this disease [11, 12] . Autophagy, a lysosome-based mechanism responsible for the degradation of cellular components, including organelles, might act as a balancing mechanism between cell survival and cell death.
Caspases and autophagy are involved in complementary death pathways in cells: in cases where caspases are inhibited, autophagy is required for cell death. In addition, signals such as steroids in flies and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) in human cells activate an autophagic cell death process that involves both active caspases and autophagy [13, 14] .
There is a need for a clinically useful chemosensitivity assay that helps to individualize the treatment delivered to cancer patients. Collagen sponge-gel supported histoculture, which maintains cellular heterogeneity and an intact cyto-architecture, has been utilized to develop the his- The goal of the current study was to examine the effi-cacy of conventional monotherapy regimens and combination therapies incorporating molecular-targeted drugs, using effects on various biological behaviors of CRC cells as endpoints.
METHODS

Cell lines
Twelve human CRC cell lines, specifically RKO, SW48, 
Anti-cancer drugs and combinations
The regimens examined included FOLFOX and 
Drug concentrations
Cytotoxicity was assessed using the CellTiter 96 Non- 
Detection of apoptosis by flow cytometry
The apoptotic effects of the respective drug regimens were studied using an Annexin V and propidium iodide (PI) double-labeling technique. In the early stages of apoptosis, the cell membrane remains intact and is imper- 
Caspase-3 activity
VEGF mRNA expression
Total RNA was prepared from control and treated cell 
Autophagy assay
Statistical analysis
All values for apoptosis and angiogenesis were pre- 
RESULTS
Effect of chemotherapeutic regimens on apoptosis
The FOLFOX regimen was more effective in promoting apoptotic cell death, measured by flow cytometry, than FOLFIRI (Table 1 ). In particular, some cells showed statistically significant differences. The FOLFOX was sig- Values present VEGFA mRNA levels after treatment with the respective regimen compared with untreated controls. Data are expressed as means ± errors of three independent experiments. VEGFA, vascular endothelial growth factor A; FOLFOX, 5-fluorouracil (5-FU) + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; B, bevacizumab; C, cetuximab. imens showed prominent activation of caspase-3, a prevalent caspase that is ultimately responsible for the majority of apoptosis processes (Fig. 2) .
Effect on angiogenesis
The effects of drug regimens on vascular endothelial growth factor A (VEGFA) mRNA levels were analyzed by quantitative real time RT-PCR. VEGFA mRNA levels were variably affected in the different cell lines ( Table 2 ). The 
Invasion assay
MMP-2 and MMP-9 activities were assayed by quantitative zymography. Both MMP-2 and MMP-9 activities were remarkably reduced in SW480 cells treated with all drug regimens, whereas the response of other cells varied according to regimens (Fig. 3) . In addition, the FOLFOX regimen more effectively reduced MMP-2 and MMP-9 activities in SW480 cells than did the FOLFIRI regimen. tients with metastatic CRC [18, 19] . In our study, monotherapy using bevacizumab and cetuximab did not induce significant tumor inhibition, but treatment with these agents in combination with FOLFOX and FOLFIRI led to significantly higher response rates than was observed with FOLFOX and FOLFIRI alone.
Autophagic cell death
Many chemotherapeutic agents mediate their cytotoxic effects by inducing apoptosis, which is generally thought to be a non-inflammatory, non-immunogenic process.
However, it has recently been suggested that apoptosis can follow biochemically distinct subroutines, some of which may result in immunogenic cell death, despite the morphological uniformity of apoptotic cell death [20, 21] .
In this context, oxaliplatin induces immunogenic apoptosis accompanied by exposure of calreticulin; oxaliplatin implantation chemotherapy of CRC mice relies on an intact immune system including the presence of toll-like receptor 4 (TLR4); and advanced CRC patients bearing a loss-of-function TLR4 allele have a lower progression-free survival after oxaliplatin-based chemotherapy than control patients with a wild-type allele [22] [23] [24] . In the current thesurgery.or.kr study, treatment combinations containing oxaliplatin led to significantly higher apoptosis rates with concurrent activation of caspase-3 than those containing irinotecan in the SW480 cells. These results suggest that oxaliplatin induces apoptotic cell death of CRC cells, and that this effect determines its therapeutic efficacy in CRC patients.
In our study, SW480 cells were the most sensitive to drug-induced apoptosis and invasion. The SW480 cell was derived from a primary Dukes' stage B (colon adenocarcinoma) tumor from a 50-year-old Caucasian male [25, 26] .
SW480 cells are considered functionally p53-deficient because the endogenous p53 protein contains two point mutations, R273H and P309S, which result in an abnormal p53 protein [27] . A study by Toscano et al. [28] reported that oxaliplatin enhances TRAIL-induced apoptosis in p53-mutant CRC cell lines, including SW480 cells [2] . In 
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